ADHD

Latest News



Adolescents evolve from child to young adult without the maturity of adulthood to help them navigate the transition, particularly when it comes to the perils of substance use and addiction. Pediatricians who care for transitional-aged youth with substance use disorders have new paradigms that have shown promise for treating addiction and its accompanying comorbidities and for sustaining recovery over time.

To help you stay abreast of research findings about widely used complementary and alternative approaches to the treatment of ADHD, you'll find results from several pivotal studies summarized here.

Before adolescents with attention-deficit/hyperactivity disorder (ADHD) head off to college and away from home, many for the first time, their pediatricians need to initiate frank discussions about how ADHD will affect them both academically and in their daily living and to help them plan a successful transition to what lies ahead.

The first brain wave test to diagnose attention-deficit/hyperactivity disorder (ADHD) will be hitting the market following recent approval by the US Food and Drug Administration (FDA).

Racial and ethnic disparities concerning the diagnosis and treatment of attention-deficit/hyperactivity disorder (ADHD) appear as early as kindergarten and persist through 8th grade, according to a new study.

New research shows that almost one-third of children aged between 4 and 8 years who are diagnosed with autism spectrum disorder (ASD) also have attention-deficit/hyperactivity disorder (ADHD).

More than 90% of pediatric subspecialists who diagnose and manage attention-deficit/hyperactivity disorder (ADHD) in young children deviate from current recommendations of the American Academy of Pediatrics (AAP) and the American Academy of Child and Adolescent Psychiatry regarding treatment of pediatric ADHD.

Children exposed to ischemic-hypoxic events in utero are at increased risk of developing attention-deficit/hyperactivity disorder (ADHD), especially those born prematurely. The findings add to growing evidence that both prenatal and postnatal factors affect neurodevelopment.

The US Food and Drug Administration (FDA) has approved extended-release methylphenidate hydrochloride oral suspension for the treatment of attention-deficit/hyperactivity disorder (ADHD). Efficacy was determined in a randomized, double-blind, crossover study that showed improvement for both attention and behavior metrics for up to 12 hours in children aged 6 to 12 years diagnosed with ADHD compared with placebo. The once-daily treatment will be available in January 2013.

A study of Canadian children found that the youngest children in the class are significantly more likely to be diagnosed with attention-deficit/hyperactivity disorder (ADHD) and prescribed medication than their peers in the same grade. Find out why overdiagnosis and overprescribing are a concern.

Results of a survey of AAP members show that most US pediatricians bypass an ECG before starting children on stimulant medication for ADHD, opting for a routine cardiac history and physical examination instead. Find out how perceived barriers to cardiac screening influence clinical practice.

Evaluations for attention-deficit/hyperactivity disorder (ADHD) should begin in children at 4 years and continue until 18 years, which significantly expands the age range for recommended screening. Released at the American Academy of Pediatrics National Conference in Boston, Massachusetts, the clinical practice guidelines recommend behavioral interventions as the first-line treatment in preschool children. The guidelines also have some new suggestions related to methylphenidate treatment for children younger than 6 years.